TD Cowen Initiates Coverage on Rapport Therapeutics (NASDAQ:RAPP)

Analysts at TD Cowen assumed coverage on shares of Rapport Therapeutics (NASDAQ:RAPP) in a note issued to investors on Tuesday, MarketBeat.com reports. The firm set a “buy” rating on the stock.

Several other research firms have also recently issued reports on RAPP. Jefferies Financial Group initiated coverage on shares of Rapport Therapeutics in a research report on Tuesday. They set a “buy” rating and a $35.00 price objective for the company. Stifel Nicolaus initiated coverage on shares of Rapport Therapeutics in a research report on Tuesday. They set a “buy” rating and a $35.00 price objective for the company.

Rapport Therapeutics Trading Down 6.8 %

Rapport Therapeutics stock opened at $23.30 on Tuesday. Rapport Therapeutics has a 12-month low of $18.00 and a 12-month high of $27.11.

Insider Buying and Selling at Rapport Therapeutics

In related news, Director James Healy purchased 44,032 shares of Rapport Therapeutics stock in a transaction dated Monday, July 1st. The shares were acquired at an average cost of $24.52 per share, with a total value of $1,079,664.64. Following the purchase, the director now owns 40,851 shares of the company’s stock, valued at $1,001,666.52. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Rapport Therapeutics Company Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.